AI Summary & Key Takeaways
AI InsightIn conclusion, serum IL-lfi levels do not increase to establish the disease activity in patients with reactive arthritis.
📌 3 Key Takeaways
Abstract
This study was performed to determine serum interleukin 1-fi (IL-l[i) levels and to investigate its relationship with disease activity in patients with reactive arthritis. Thirty-one reactive arthritis patients and 21 healthy control subjects were enrolled into the study. Although serum IL-lfi levels were found to be higher in patient group when compared to those of control group, this difference was not statistically significant. Furthermore, serum IL-lfi levels showed no relationship with erythrocyte sedimentation rate and C-reactive protein, which are markers of acute phase response. In conclusion, serum IL-lfi levels do not increase to establish the disease activity in patients with reactive arthritis. Therefore, serum IL-lfi levels are not useful to evaluate the disease activity in such cases.
Özet
Bu caltsma reaktif artritli hastalarda serum interlokin 1-fi (IL-lp) duzeylerini olcmek ve biinun hastaligm aktivitesi He ilskisini degerlendirmek amaciyla yapilmistir. gahsma 31 reaktif artritli ve 21 saghkh kontrol vakasi He yapilmi§tir. Qahsmada reaktif artritli hastalartn serum IL-lfi diizeyleri kontrol grubuna oranla daha yiiksek bulunmus olmasma ragmen, bu farkhhk istatistiksel acidan anlamh bulunmamistir. Ayrtca serum IL-lfi diizeyleri, akut faz cevabi gostergeleri olan sedimentasyon ve C- reaktif protein He de iliskili bulunmamistir. Sonug olarak, serum IL-lfi duzeylerinin reaktif artritli hastalarda hastahgin aktivitesini gosterecek sekilde artmadigmi ortaya koyduk. Dolayisiyla serum IL-lfi olgilmu reaktif artritli hastalarda hastahk aktivitesini belirlemede yararh bir gosterge degildir.